Embedded Files
Lexi Ventures is a top-20 investor in gene tech startups.
This focus is rooted in these beliefs.
We are at a point in the arc of human innovation where we are learning how to program and analyze DNA, RNA, and proteins
This will change the lives of all people to a degree comparable with the industrial and info-tech revolutions.
Companies applying genetics will create large opportunities for wealth creation for their customers, employees, and investors.
In the coming 10 years, there will be more alpha in gene tech than most other venture investments.
Gene tech startups aim to cure many of the worst and most expensive diseases, improving happiness and reducing healthcare needs. Other gene tech startups will enable plants and microbes to produce newer and better things while sustaining the natural environment.
Lexi Ventures is one of the only investors concentrated exclusively in gene tech with diversification across industries.
For Startups
Lexi Ventures provides seed stage funding for US-based startups applying or enabling genomics or synthetic biology.
Most investments that Lexi Ventures considers are naturally described using the key words DNA, RNA, protein, or cell.
Lexi Ventures occasionally considers pre-seed funding rounds of particularly promising companies and post-seed rounds with particularly attractive terms.
Please connect if you are working on any of these.
A novel type of cell or gene therapy
Diagnostics using DNA, RNA, or proteins
Genetically engineered plants or microbes
Related software, chemistry, or devices
Lexi Ventures tends not to invest in
Small molecules
Therapeutic assets
Medical devices
Consumer-facing software
Jonah Probell
Founder and Managing Partner
Prior to finance, Jonah held engineering, executive, and founder roles in 7 startups. He achieved 2 IPOs, 16 granted patents and wrote 2 books.
Jonah has a lifelong interest in science, engineering, economics, philosophy, and innovation. He invests for maximum realized IRR.
Report abuse